"Making cancer drugs less expensive" linking clinical value to price

In an opinion piece in the Washington Post, Hagop Kantarjian, Leonard Zwelling, and Tito Fojo offer a perspective on cancer drug prices as well as advice on how to reduce prices. "We believe that the price of cancer drugs is too high. Those already-high prices, which continue to rise rapidly, are an increasingly significant issue in U.S. health-care expenditures." Continue reading here.